JCT  Vol.4 No.10 , December 2013
Association between Pretreatment Levels of Serum Vascular Endothelial Growth Factor (VEGF) and Survival Outcomes in Locally Advanced Cervical Cancer Patients
Abstract: Objective: To evaluate the association between pretreatment levels of serum vascular endothelial growth factor (VEGF) and long-term treatment outcomes in patients with locally advanced cervical cancer (LACC). Methods: Thirty-nine patients diagnosed with LACC (stage IIB-IVA) and obtaining blood for serum VEGF were identified. All patients received complete treatment as radical radiotherapy with or without concurrent chemotherapy. Surveillance for all patients was every 3 months during the first 2 years, and every 6 months later. Results: Mean age of 39 patients was 52.3 ± 10.8 years old. Twenty-three patients (59.0%) had stage IIB, and 16 patients (41.0%) had stage IIIB. Histological cell type was mostly squamous cell carcinoma (89.7%). The median and 75th percentile level of serum VEGF were 610.2 pg/ml (0.0 - 4067.2 pg/ml) and 825.6 pg/ml, respectively. At median follow-up of 37.0 months (range, 26.8 - 46.3 months), the 3-year OS rate was 78.6%. Clinical stage (p = 0.04) and 75th percentile of VEGF level (p = 0.04) were impacted on OS in univariable analysis. The 3-year OS of patients in stage IIB with serum VEGF of ≤825.6 pg/ml and of > 825.6 pg/ml was slightly different, 94.4% and 80.0% respectively (p = 0.34), whereas there were many differences in stage IIIB, 71.4% and 25.0% in patients with serum VEGF of ≤825.6 pg/ml and of >825.6 pg/ml respectively (p = 0.05). Conclusion: High pretreatment serum VEGF level has an influence on OS for LACC. It is potentially used as a predictive factor, especially in patients stage IIIB, in order to provide efficient treatment and improve survival outcomes in the future.
Cite this paper: K. Katanyoo, K. Rongsriyam and M. Chongtanakon, "Association between Pretreatment Levels of Serum Vascular Endothelial Growth Factor (VEGF) and Survival Outcomes in Locally Advanced Cervical Cancer Patients," Journal of Cancer Therapy, Vol. 4 No. 10, 2013, pp. 1478-1484. doi: 10.4236/jct.2013.410178.

[1]   A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward and D. Forman, “Global Cancer Statistics,” CA: A Cancer Journal for Clinicians, Vol. 61, No. 2, 2011, pp. 69-90.

[2]   R. Pearcey, M. Brundage, P. Drouin, J. Jeffery, D. Johnston, H. Lukka, et al., “Phase III Trial Comparing Radical Radiotherapy with and without Cisplatin Chemotherapy in Patients with Advanced Squamous Cell Cancer of the Cervix,” Journal of Clinical Oncology, Vol. 20, No. 4, 2002, pp. 966-972.

[3]   Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration, “Reducing Uncertainties about the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data from 18 Randomized Trials,” Journal of Clinical Oncology, Vol. 26, No. 35, 2008, pp. 5802-5812.

[4]   P. Carmeliet and R. K. Jain, “Angiogenesis in Cancer and Other Diseases,” Nature, Vol. 407, No. 6801, 2000, pp. 249-257.

[5]   J. D. Carpini, A. K. Karam and L. Montgomery, “Vascular Endothelial Growth Factor and Its Relationship to the Prognosis and Treatment of Breast, Ovarian and Cervical Cancer,” Angiogenesis, Vol. 13, No. 1, 2010, pp. 43-58.

[6]   H. S. Moon, S. C. Kim, J. J. Aha and B. H. Woo, “Concentration of Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor-β1 (TGF-β1) in the Serum of Patients with Cervical Cancer: Prediction of Response,” International Journal of Gynecological Cancer, Vol. 10, No. 2, 2000, pp. 151-156.

[7]   X. P. Peng, J. D. Li, M. D. Li, X. M. Ye and W. C. Yan, “Clinical Significance of Vascular Endothelial Growth Factor in Sera of Patients with Gynecological Malignant Tumors,” Chinese Journal of Cancer, Vol. 21, 2002, pp. 181-185.

[8]   A. Lebrecht, E. Ludwig, A. Huber, M. Klein, C. Schneeberger, C. Tempfer, et al., “Serum Vascular Endothelial Growth Factor and Serum Leptin in Patients with Cervical Cancer,” Gynecologic Oncology, Vol. 85, No. 1, 2002, pp. 32-35.

[9]   B. Bachtiary, E. Selzer, T. H. Knocke, R. Potter and A. Obermair, “Serum VEGF Levels in Patients Undergoing Primary Radiotherapy for Cervical Cancer: Impact on Progression-Free Survival,” Cancer Letters, Vol. 179, No. 2, 2002, pp. 197-203.

[10]   S. P. Mathur, R. S. Mathur, E. A. Gray, D. Lane, P. G. Underwood, M. Kohler, et al., “Serum Vascular Endothelial Growth Factor C (VEGF-C) as a Specific Biomarker for Advanced Cervical Cancer: Relationship to Insulin-Like Growth Factor II (IGF-II), IGF Binding Protein 3 (IGF-BP3) and VEGF-B,” Gynecologic Oncology, Vol. 98, No. 3, 2005, pp. 467-483. 05.003

[11]   P. L. M. Zusterzeel, P. N. Span, M. G. K. Dijksterhuis, C. M. G. Thomas, F. C. G. J. Sweep and L. F. A. G. Massuger, “Serum Vascular Endothelial Growth Factor: A Prognostic Factor in Cervical Cancer,” Journal of Cancer Research and Clinical Oncology, Vol. 135, No. 2, 2009, pp. 283-290.

[12]   S. Srivastava, A. Gupta, G. G. Agarwal, S. M. Natu, S. Uma, M. M. Goel, et al., “Correlation of Serum Vascular Endothelial Growth Factor with Clinicopathological Parameters in Cervical Cancer,” Bioscience Trends, Vol. 3, 2009, pp. 144-150.

[13]   K. Katanyoo, A. Chantarasri, M. Chongtanakon, K. Rongsriyam and T. Tantivatana, “Pretreatment Levels of Serum Vascular Endothelial Growth Factor Do Not Correlate with Outcome in Patients with Locally Advanced Cervical Cancer,” Asian Pacific Journal of Cancer Prevention, Vol. 12, No. 3, 2011, pp. 1-6.

[14]   M. Biedka, R. Makarewicz, A. Marzalek, H. Kardymowicz and A. Goralewska, “Labeling in Microvessel Density, Lymphatic Vessel, Density and Potential Role of Proangiogenic and Lymphangiogenic Factors as a Predictive/Prognostic Factors after Radiotherapy in Patients with Cervical Cancer,” European Journal of Gynaecological Oncology, Vol. 33, No. 4, 2012, pp. 399-405.

[15]   A. Gadducci, R. Tana, S. Cosio and A. R. Genazzani, “The Serum Assay of Tumour Markers in the Prognostic Evaluation, Treatment Monitoring and Follow-Up of Patients with Cervical Cancer: A Review of the Literature,” Critical Reviews in Oncology/Hematology, Vol. 66, No. 4, 2008, pp. 10-20.

[16]   F. Forni, G. Ferrandina, F. Deodato, G. Macchia, A. G. Morganti, D. Smaniotto, et al., “Squamous Cell Carcinoma Antigen in Follow-Up of Cervical Cancer Treated with Radiotherapy: Evaluation of Cost-Effectiveness,” International Journal of Radiation Oncology, Biology, Physics, Vol. 69, No. 4, 2007, pp. 1145-1149.

[17]   R. A. Burger, “Role of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Gynecologic Malignancies,” Journal of Gynecologic Oncology, Vol. 21, No. 1, 2010, pp. 3-11. 3802/jgo.2010.21.1.3

[18]   L. P. Garrison, D. Lubeck, D. Lalla, V. Paton, A. Dueck and E. A. Perez, “Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Setting for Treatment of HER2-Positive Breast Cancer,” Cancer, Vol. 110, No. 3, 2007, pp. 489-498.

[19]   N. L. Liberato, M. Marchetti and G. Barosi, “Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer,” Journal of Clinical Oncology, Vol. 25, No. 22, 2007, pp. 625-633.

[20]   J. Norum, “The Cost-Effectiveness Issue of Adjuvant Trastuzumab in Early Breast Cancer,” Expert Opinion on Pharmacotherapy, Vol. 7, No. 12, 2006, pp. 1617-1625. 656566.7.12.1617